Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients

被引：0
作者：
R Launois
L Riou Franca
B Guidet
P Aegerter
X Huet
P Meshaka
P Pinton
机构：
[1] REES France,Biostatistique et Informatique médicale
[2] Réseau d'Evaluation en Economie de la Santé,undefined
[3] Hôpital Saint Antoine,undefined
[4] Hôpital Ambroise Paré,undefined
[5] Laboratoire Lilly France,undefined
来源：
Critical Care | / 6卷 / Suppl 1期
关键词：
Severe Sepsis; Cost Effectiveness Ratio; Expected Cost; Drotrecogin Alfa; Differential Cost;
D O I：
10.1186/cc1570
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[41]   How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design [J].
Andre C. Kalil ;
Junfeng Sun .
Intensive Care Medicine, 2008, 34
[42]   Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals [J].
Dombrovskiy, Viktor ;
Martin, Andrew ;
Sunderram, Jagadeeshan ;
Paz, Harold .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (12) :1151-1156
[43]   Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated) [J].
Annane, Djillali ;
Mira, Jean Paul ;
Ware, Lorraine B. ;
Gordon, Anthony C. ;
Sevransky, Jonathan ;
Stueber, Frank ;
Heagerty, Patrick J. ;
Wellman, Hugh F. ;
Neira, Mauricio ;
Mancini, Alexandra D. J. ;
Russell, James A. .
ANNALS OF INTENSIVE CARE, 2012, 2
[44]   Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated) [J].
Djillali Annane ;
Jean Paul Mira ;
Lorraine B Ware ;
Anthony C Gordon ;
Jonathan Sevransky ;
Frank Stüber ;
Patrick J Heagerty ;
Hugh F Wellman ;
Mauricio Neira ;
Alexandra DJ Mancini ;
James A Russell .
Annals of Intensive Care, 2
[45]   Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated) [J].
Andrew F Shorr ;
Jonathan M Janes ;
Antonio Artigas ;
Jyrki Tenhunen ;
Duncan LA Wyncoll ;
Emmanuelle Mercier ;
Bruno Francois ;
Jean-Louis Vincent ;
Burkhard Vangerow ;
Darell Heiselman ;
Amy G Leishman ;
Yajun E Zhu ;
Konrad Reinhart .
Critical Care, 14
[46]   Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis [J].
Djillali Annane ;
Jean-Paul Mira ;
Lorraine B. Ware ;
Anthony C. Gordon ;
Charles J. Hinds ;
David C. Christiani ;
Jonathan Sevransky ;
Kathleen Barnes ;
Timothy G. Buchman ;
Patrick J. Heagerty ;
Robert Balshaw ;
Nadia Lesnikova ;
Karen de Nobrega ;
Hugh F. Wellman ;
Mauricio Neira ;
Alexandra D. J. Mancini ;
Keith R. Walley ;
James A. Russell .
Annals of Intensive Care, 8
[47]   Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis [J].
Annane, Djillali ;
Mira, Jean-Paul ;
Ware, Lorraine B. ;
Gordon, Anthony C. ;
Hinds, Charles J. ;
Christiani, David C. ;
Sevransky, Jonathan ;
Barnes, Kathleen ;
Buchman, Timothy G. ;
Heagerty, Patrick J. ;
Balshaw, Robert ;
Lesnikova, Nadia ;
de Nobrega, Karen ;
Wellman, Hugh F. ;
Neira, Mauricio ;
Mancini, Alexandra D. J. ;
Walley, Keith R. ;
Russell, James A. .
ANNALS OF INTENSIVE CARE, 2018, 8
[48]   Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study [J].
Salmaan Kanji ;
Marc M. Perreault ;
Clarence Chant ;
David Williamson ;
Lisa Burry .
Intensive Care Medicine, 2007, 33 :517-523
[49]   Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study [J].
Kanji, Salmaan ;
Perreault, Marc M. ;
Chant, Clarence ;
Williamson, David ;
Burry, Lisa .
INTENSIVE CARE MEDICINE, 2007, 33 (03) :517-523
[50]   The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies [J].
Machala, W ;
Wachowicz, N ;
Komorowska, A ;
Gaszynski, W .
MEDICAL SCIENCE MONITOR, 2004, 10 (07) :CS31-CS36
12345